Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 128

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 128
---
 or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s
first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard
to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States
patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard
to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard
to that License IP is terminated.

The Agreement may be terminated by either party in
the event of a material breach by the other party.

On December 17, 2018 Regen Biopharma, Inc.(“Licensor”)
, KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT
AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned
Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights,
duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties
and obligations thereunder and be bound to the terms of the Agreement with respect thereto.

| 102 |

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”),
KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”)
whereby:

1) Zander shall return for cancellation 194,285,714
shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of
principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount
due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen
(“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen
by